20-[[1-Carboxy-4-[(1-carboxy-4-oxopentyl)amino]-4-oxobutyl]amino]-20-oxoicosanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 20-[[1-Carboxy-4-[(1-carboxy-4-oxopentyl)amino]-4-oxobutyl]amino]-20-oxoicosanoic acid
• 英文别名: 20-[[1-carboxy-4-[(1-carboxy-4-oxopentyl)amino]-4-oxobutyl]amino]-20-oxoicosanoic acid
• 化学式: C₃₁H₅₄N₂O₉
• 分子量: 598.8
• InChiKey: KEAVLPHOXMANDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  42
• 可旋转键数：
  29
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  187
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• POLYPEPTIDES AND USES THEREOF
  申请人：MEDIMMUNE LIMITED

  公开号：US20220204580A1

  公开（公告）日：2022-06-30

  Disclosed are polypeptides which are pramlintide analogues and uses thereof. In particular, the present invention relates to polypeptides of SEQ ID NO 2 which are pramlintide analogues conjugated to half-life extending moieties such as albumin binding moieties and uses thereof.
• [EN] OXYNTOMODULIN MIMETICS<br/>[FR] MIMÉTIQUES D'OXYNTOMODULINE
  申请人：KEYBIOSCIENCE AG

  公开号：WO2021148664A1

  公开（公告）日：2021-07-29

  Disclosed herein are oxyntomodulin mimetics, and their use as medicaments in the treatment of various diseases and disorders including, but not limited to, excess bodyweight, excessive food consumption, metabolic syndrome, non-alcoholic steatohepatitis, alcoholic and non-alcoholic fatty liver disease, diabetes (Type I and Type II), obesity, the regulation of blood glucose levels, the regulation of response to glucose tolerance tests, and the regulation of food intake.